We are live on ! Find out more
BGA

Belmont Global Advisors Portfolio holdings

AUM $106M Turnover 61.46%
1-Year Est. Return 2.89%
This Fund
S&P 500
This Quarter Est. Return
+8.71%
1 Year Est. Return
-2.89%
3 Year Est. Return
+81.05%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$106M
AUM Growth
+$1.54M
Cap. Flow
+$1.48M
Cap. Flow %
1.4%
Top 10 Hldgs %
66.08%
Holding
96
New
32
Increased
14
Reduced
12
Closed
27
Avg Time Held Equity + Options
0.5 years
Top 10 Avg Time Held Equity + Options
0.7 years
Top 20 Avg Time Held Equity + Options
0.6 years
Avg Time Held Equity only
0.5 years
Top 10 Avg Time Held Equity only
0.6 years
Top 20 Avg Time Held Equity only
0.7 years

Top Buys

Rank Stock Value
1
TCRT icon
Alaunos Therapeutics
TCRT
+$2.18M
2
IMPV
Imperva, Inc.
IMPV
+$1.32M
3
BDSI
BioDelivery Sciences International, Inc.
BDSI
+$1.08M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$1.06M
5
BBW icon
Build-A-Bear
BBW
+$979K

Top Sells

Rank Stock Value
1
ACAD icon
Acadia Pharmaceuticals
ACAD
+$1.29M
2
HD icon
Home Depot
HD
+$1.28M
3
PANW icon
Palo Alto Networks
PANW
+$1.04M
4
LJPC
La Jolla Pharmaceutical Company
LJPC
+$960K
5
CHKP icon
Check Point Software Technologies
CHKP
+$797K

Sector Composition

Rank Sector Weight
1 Miscellaneous 51.6%
2 Healthcare 26.08%
3 Technology 7.28%
4 Consumer Discretionary 3.69%
5 Industrials 2.65%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
TCRT icon
1
CALL
Alaunos Therapeutics
TCRT
$6.68M
$15.7M 14.83%
18,561
+2,528
+16% +$2.03M
2014 Q2
9 quarters
PGEN icon
2
CALL
Precigen
PGEN
$2.28B
$12.7M 12.06%
459,095
-20,180
-4% -$534K
2015 Q4
3 quarters
TCRT icon
3
Alaunos Therapeutics
TCRT
$6.68M
$12.5M 11.85%
14,835
+2,715
+22% +$2.18M
2013 Q4
11 quarters
QQQ icon
4
PUT
Invesco QQQ Trust
QQQ
$479B
$11.9M 11.23%
+100,000
New +$11.5M
2016 Q3
0 quarters
PGEN icon
5
Precigen
PGEN
$2.28B
$8.42M 7.97%
303,255
+20,180
+7% +$534K
2013 Q4
11 quarters
MNDT
6
CALL
DELISTED
Mandiant, Inc. Common Stock
MNDT
$2.21M 2.09%
+150,000
New +$2.3M
2016 Q3
0 quarters
VBTX icon
7
DELISTED
Veritex Holdings
VBTX
$1.66M 1.57%
95,404
+1,175
+1% +$20K
2014 Q4
7 quarters
FBIO icon
8
Fortress Biotech
FBIO
$62.4M
$1.62M 1.53%
36,333
-334
-0.9% -$14.2K
2015 Q1
6 quarters
ACAD icon
9
CALL
Acadia Pharmaceuticals
ACAD
$3.29B
$1.59M 1.51%
50,000
-100,000
-67% -$3.39M
2016 Q2
1 quarter
IMPV
10
DELISTED
Imperva, Inc.
IMPV
$1.53M 1.45%
+28,500
New +$1.32M
2016 Q3
0 quarters
SGYP
11
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$1.49M 1.41%
270,000
-115,000
-30% -$538K
2015 Q1
6 quarters
AMZN icon
12
Amazon
AMZN
$2.7T
$1.26M 1.19%
30,160
– –
2016 Q1
2 quarters
AIRM
13
CALL
DELISTED
Air Methods Corp
AIRM
$1.26M 1.19%
+40,000
New +$1.36M
2016 Q3
0 quarters
MNDT
14
DELISTED
Mandiant, Inc. Common Stock
MNDT
$1.19M 1.13%
81,000
+21,000
+35% +$323K
2016 Q2
1 quarter
GLD icon
15
SPDR Gold Trust
GLD
$141B
$1.18M 1.12%
9,265
+7,415
+401% +$944K
2016 Q2
1 quarter
MSFT icon
16
Microsoft
MSFT
$3.93T
$1.16M 1.09%
20,055
– –
2016 Q1
2 quarters
BDSI
17
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$1.15M 1.09%
+425,000
New +$1.08M
2016 Q3
0 quarters
CYTK icon
18
CALL
Cytokinetics
CYTK
$8.61B
$1.1M 1.04%
+120,000
New +$1.25M
2016 Q3
0 quarters
SGYP
19
CALL
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$1.1M 1.04%
+200,000
New +$936K
2016 Q3
0 quarters
BHK icon
20
BlackRock Core Bond Trust
BHK
$602M
$1.07M 1.01%
75,069
+1,455
+2% +$20.5K
2016 Q1
2 quarters
LXU icon
21
LSB Industries
LXU
$765M
$1.03M 0.97%
156,000
+104,000
+200% +$884K
2016 Q2
1 quarter
ALNY icon
22
Alnylam Pharmaceuticals
ALNY
$31B
$1.02M 0.96%
+15,000
New +$1.06M
2016 Q3
0 quarters
META icon
23
Meta Platforms (Facebook)
META
$1.81T
$1.01M 0.95%
7,860
+160
+2% +$19.9K
2013 Q4
11 quarters
ORLY icon
24
O'Reilly Automotive
ORLY
$72.2B
$984K 0.93%
52,680
– –
2014 Q3
8 quarters
OSPN icon
25
OneSpan
OSPN
$645M
$880K 0.83%
+50,000
New +$879K
2016 Q3
0 quarters
1
2 3 4

Similar funds

LOT
Lombard Odier Transatlantic Montreal, Quebec, Canada $105M AUM 10.28% 1-Year Est. Return
EC
Eachwin Capital New York $108M AUM 14.45% 1-Year Est. Return
SAMNY
Samsung Asset Management (New York) New York $109M AUM 14.33% 1-Year Est. Return
DCMM
DG Capital Management (Massachusetts) Boston, Massachusetts $102M AUM 29.14% 1-Year Est. Return
PCM
Panning Capital Management New York $97.5M AUM 302.5% 1-Year Est. Return
SVGI
Sapphire Ventures (GPE) I Palo Alto, California $115M AUM 11.63% 1-Year Est. Return
EDRM
Edmond de Rothschild (Monaco) Monaco $116M AUM
EDRAML
Edmond de Rothschild Asset Management (Luxembourg) Luxembourg $95.2M AUM 19.45% 1-Year Est. Return

Belmont Global Advisors's Q3 2016 Portfolio in Review

As of Q3 2016, Belmont Global Advisors held 96 positions worth $106M, up 1.5% from $104M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Belmont Global Advisors's Q3 2016 filing shows 32 new, 14 increased, 12 reduced and 27 closed positions. Its largest new stake was Imperva, Inc.: 28,500 shares worth $1.53M. The largest sale was Acadia Pharmaceuticals, an estimated $1.29M.

By sector, the portfolio is most concentrated in Miscellaneous at 52% of assets, down from 56% a quarter earlier, followed by Healthcare and Technology.

  • Belmont Global Advisors's largest Q3 2016 buy was Imperva, Inc.: 28,500 shares worth $1.53M.
  • Belmont Global Advisors added most to Alaunos Therapeutics in Q3 2016, an estimated $2.18M increase.
  • Belmont Global Advisors's biggest Q3 2016 reduction was Fate Therapeutics, cutting an estimated $607K.
  • Belmont Global Advisors fully exited Acadia Pharmaceuticals in Q3 2016, selling an estimated $1.29M.
  • Belmont Global Advisors's ten largest holdings make up 66% of its $106M portfolio in Q3 2016.
  • Belmont Global Advisors opened 32 new positions and closed 27 in Q3 2016.
  • Belmont Global Advisors's portfolio value rose 1.5% quarter-over-quarter to $106M.

Based on Belmont Global Advisors's 13F filing for Q3 2016, filed 14 Nov 2016.